Brimonidine Tartrate/Timolol Maleate 2 mg/mL
Brimonidine Tartrate and Timolol Maleate · SOLUTION/ DROPS · ARMAS PHARMACEUTICALS INC
Brimonidine Tartrate/Timolol Maleate is a solution/ drops containing brimonidine tartrate and timolol maleate at 2 mg/mL, taken ophthalmic. Manufactured by ARMAS PHARMACEUTICALS INC.
Key Facts
- Brand Name
- Brimonidine Tartrate/Timolol Maleate
- Generic Name
- Brimonidine Tartrate and Timolol Maleate
- NDC Code (Product)
72485-634- Manufacturer
- ARMAS PHARMACEUTICALS INC
- Strength
- 2 mg/mL
- Dosage Form
- SOLUTION/ DROPS
- Route
- OPHTHALMIC
- Marketing Status
- Application #
- ANDA201949
- Marketing Start
- 11/03/2023
Recall History
Apotex Corp.
Lack of Assurance of Sterility
Apotex Corp.
Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
Allergan Sales, LLC
Failed Impurities/Degradation Specifications.
Apotex Corp.
Lack of Assurance of Sterility
Allergan Sales, LLC
cGMP Deviations
Side Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
1 INDICATIONS AND USAGE Brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of brimonidine tartrate/timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. Brimonidine Tartrate/Timolol Maleate is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of brimonidine tartrate/timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% …
Dosage & Administration
2 DOSAGE AND ADMINISTRATION The recommended dose is one drop of brimonidine tartrate/timolol maleate ophthalmic solution in the affected eye(s) twice daily approximately 12 hours apart. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. One drop in the affected eye(s), twice daily approximately 12 hours apart. ( 2 )
Contraindications
4 CONTRAINDICATIONS Bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease. ( 4.1 , 5.1 , 5.3 ) Sinus bradycardia, atrioventricular block, overt cardiac failure, cardiogenic shock. ( 4.2 , 5.2 ) Neonates and infants (under the age of 2 years). ( 4.3 ) Hypersensitivity to any component of this product. ( 4.4 ) 4.1 Reactive Airway Disease Including Asthma, COPD Brimonidine tartrate/timolol maleate ophthalmic solution is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see Warnings and Precautions ( 5.1 , 5.3 )] . 4.2 Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock Brimonidine tartrate/timolol maleate ophthalmic solution is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure [see Warnings and Precautions ( 5.2 )] ; cardiogenic shock. 4.3 Neonates and Infants (Under the Age of 2 Years) Brimonidine tartrate/timolol maleate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years). 4.4 Hypersensitivity Reactions Local hyper…
Drug Interactions
7 DRUG INTERACTIONS Antihypertensives/cardiac glycosides may lower blood pressure. ( 7.1 ) Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. ( 7.2 ) Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. ( 7.3 ) Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia. ( 7.4 ) Use with CNS depressants may result in an additive or potentiating effect. ( 7.5 ) Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. ( 7.6 ) CYP2D6 inhibitors may potentiate systemic beta-blockade. ( 7.7 ) Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. ( 7.8 ) Monoamine oxidase inhibitors may result in increased hypotension. ( 7.9 ) 7.1 Antihypertensives /Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. 7.2 Beta-adrenergic Blocking Agents P…
Adverse Reactions
6 ADVERSE REACTIONS Most common adverse reactions occurring in approximately 5 to 15% of patients included allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sentiss at 1-855-473-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. B rimonidine t artrate / t imolol m aleate o phthalmic solution In clinical trials of 12 months duration with brimonidine tartrate/timolol maleate ophthalmic solution the most frequent reactions associated with its use occurring in approximately 5% to 15% of the patients included: allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging. The following adverse reactions were reported in 1% to 5% of patients: asthenia, blepharitis, corneal erosion, depression, epiphora, eye dis…
Frequently Asked Questions
What is Brimonidine Tartrate/Timolol Maleate used for?
Brimonidine Tartrate/Timolol Maleate contains Brimonidine Tartrate and Timolol Maleate. It is a solution/ drops taken ophthalmic. Consult your doctor for specific uses.
Is Brimonidine Tartrate/Timolol Maleate a controlled substance?
Brimonidine Tartrate/Timolol Maleate is not classified as a controlled substance by the DEA.
What is the generic name for Brimonidine Tartrate/Timolol Maleate?
The generic name for Brimonidine Tartrate/Timolol Maleate is Brimonidine Tartrate and Timolol Maleate. There are 11 other brand versions of Brimonidine Tartrate and Timolol Maleate.
What is the NDC code for Brimonidine Tartrate/Timolol Maleate 2 mg/mL?
The NDC (National Drug Code) for Brimonidine Tartrate/Timolol Maleate 2 mg/mL is 72485-634, listed by ARMAS PHARMACEUTICALS INC.
Other Brimonidine Brands
See all →- Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution2 mg/mL65145-162
- Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution2 mg/mL60505-0589
- Brimonidine Tartrate and Timolol Maleate2 mg/mL62332-706
- Brimonidine Tartrate and Timolol Maleate2 mg/mL70069-651
- Brimonidine Tartrate and Timolol Maleate2 mg/mL46708-706
- Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution2 mg/mL65145-163
- Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution2 mg/mL65145-164
- Brimonidine Tartrate and Timolol Maleate2 mg/mL70069-652
- Brimonidine tartrate and Timolol maleate2 mg/mL72603-931
- Brimonidine Tartrate and Timolol Maleate2 mg/mL0781-7186
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)